Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 13 cyclopia sequence 7 Neoplasms 5 Polycystic Ovary Syndrome 4 Prostatic Neoplasms 3 Multiple Myeloma 3 Lung Neoplasms 3 Leiomyoma 3 Head and Neck Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Vomiting 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Pain 2 Obesity 2 Neoplasms, Plasma Cell 2 Nausea 2 Hematologic Diseases 2 Fatigue 2 Depression 2 Weight Loss 1 Warts 1 Urinary Bladder Neoplasms 1 Testicular Neoplasms 1 Sleepiness 1 Sezary Syndrome 1 Prostatic Intraepithelial Neoplasia 1 Primary Myelofibrosis 1 Peripheral Nervous System Diseases 1 Pediatric Crohn's disease 1 Pdgfra-Associated Chronic Eosinophilic Leukemia 1

Interventions

Ipilimumab 98 pembrolizumab 84 Nivolumab 82 aldesleukin 51 Cyclophosphamide 49 Interleukin-2 38 fludarabine phosphate 31 Vemurafenib 31 Dacarbazine 31 dabrafenib 29 trametinib 28 Temozolomide 26 fludarabine 25 CTLA-4 Antigen 18 Bevacizumab 18 Radiosurgery 15 Paclitaxel 15 Carboplatin 14 encorafenib 13 binimetinib 13 Introns 13 talimogene laherparepvec 12 Radiotherapy 12 Interferon alpha-2 12 spartalizumab 11 cobimetinib 10 atezolizumab 10 sargramostim 9 peginterferon alfa-2b 9 montanide ISA 51 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Melanoma × Sugars × Clear all

NCT04899921 2024-03-26

Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets

Dana-Farber Cancer Institute

Phase 2 Terminated

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡